Genzyme Corp.’s research and development operations in Massachusetts have been cut by an unspecified number of positions, according to parent company Sanofi (NYSE: SNY). The positions have been eliminated to avoid redundancy between Sanofi and Genzyme staff, and do not reflect cuts to any specific drug development programs, the firm said.
